AI-powered diagnostic radiogenomics devices market seen reaching $1.5B by 2030

The market for AI-powered diagnostic radiogenomics devices is projected to grow from $0.62 billion in 2025 to $1.5 billion by 2030, driven by precision medicine, imaging-genomics integration and rising demand for AI-enabled clinical decision tools. North America led the market in 2025, while Asia-Pacific is expected to grow fastest.

Why it matters: - AI-powered diagnostic radiogenomics devices are moving deeper into precision medicine, where imaging and genomic data are used together to improve diagnosis and treatment selection. - The market forecast points to fast growth in healthcare tools that can support earlier detection, more individualized care and better therapy response prediction. - The shift matters most in oncology and neurology, where precision diagnostics and predictive analytics are gaining more clinical use.

What happened: - The Business Research Company released a 2026 market report on AI-powered diagnostic radiogenomics devices. - The report values the market at $0.62 billion in 2025 and projects $0.74 billion in 2026. - The report forecasts the market will reach $1.5 billion by 2030. - The report estimates a 19.2% CAGR for the historical period and a 19.5% CAGR through 2030. - The report was published June 29, 2026, from London.

The details: - AI-powered diagnostic radiogenomics devices combine imaging data with genomic and molecular profiles using artificial intelligence algorithms. - The systems are designed to link radiographic features with genetic expression patterns. - The devices support disease classification, risk assessment and treatment-response prediction at the individual level. - The report cites rising chronic and complex disease prevalence as a major historical growth driver. - Wider adoption of advanced diagnostic imaging technologies also supported growth. - Investment in precision medicine research, genomic sequencing and molecular profiling has expanded the market base. - Demand for data-driven clinical decision-making tools continues to rise. - Future growth is expected to be driven by AI-enabled personalized treatment planning. - Cloud-based radiogenomic data analytics platforms are gaining traction. - Genomics is being more deeply integrated into diagnostic imaging workflows. - The report also points to rising investment in precision diagnostics for oncology and neurology. - Other growth drivers include stronger early-detection efforts and development of predictive healthcare technologies. - Key trends include multimodal imaging paired with genomics, precision diagnostic solutions tailored to individuals, predictive analytics for prognosis and therapy-response evaluation, automated radiogenomic interpretation tools and real-time clinical decision support. - The report includes coverage of Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America and the Middle East and Africa. - The report offers a free sample and the full report online: Download the sample and view the full report.

Between the lines: - Precision medicine is the clearest demand signal behind the market forecast. - The reported FDA personalized-therapy approvals suggest the clinical ecosystem is already shifting toward treatments that rely on genomic data. - North America's current lead suggests a mature adoption base, while faster Asia-Pacific growth points to broader global uptake ahead. - The report's focus on cloud analytics and automated interpretation signals a move from specialized research use toward more workflow-integrated clinical tools.

What's next: - Market growth is expected to remain tied to precision diagnostics investment, especially in cancer and neurological care. - Adoption should continue to rise as imaging and genomics become more tightly linked in clinical workflows. - The report says the next wave of products will likely emphasize predictive analytics, real-time decision support and automation.

The bottom line: - AI-powered diagnostic radiogenomics is emerging as a high-growth niche at the intersection of imaging, genomics and precision medicine.